Medical treatment for biochemical relapse after radiotherapy

Cancer/Radiotherapie

Volumn 18, Issue 5-6, 2014, Pages 540-544

  Quero, L ^a   Hennequin, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Biochemical relapse; Prostate cancer; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDICAL HISTORY; METASTASIS; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RETROSPECTIVE STUDY; SHORT SURVEY; ADENOCARCINOMA; BLOOD; DISEASE COURSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; MALE; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SECONDARY; WATCHFUL WAITING;

5-ALPHA REDUCTASE INHIBITORS; ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; WATCHFUL WAITING;

EID: 84907408098     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2014.06.007     Document Type: Short Survey

References (49)

1. Ray M., Thames H., Levy L., Horwitz E., Kupelian P., Martinez A., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150.
2. Thames H., Kuban D., Levy L., Horwitz E., Kupelian P., Martinez A., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003, 15:929-943.
3. Roach M., Hanks G., Thames H., Schellhammer P., Shipley W., Sokol G., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
4. Boorjian S.A., Thompson R.H., Tollefson M.K., Rangel L.J., Bergstralh E.J., Blute M.L., et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011, 59:893-899.
5. Antonarakis E.S., Chen Y., Elsamanoudi S.I., Brassell S.A., Da Rocha M.V., Eisenberger M.A., et al. Long-term overall survival and metastasis-free survival for men with prostate specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2011, 108:378-385.
6. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433-439.
7. D'Amico A., Mould J., Carroll P., Sun L., Lubeck D., Chen M. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol 2003, 21:2163-2172.
8. Patel A., Dorey F., Franklin J., de Kernion J.B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and logslope prostate specific antigen. J Urol 1997, 158:1441-1445.
9. Kupelian P., Buchsbaum J., Patel C., Elshaikh M., Reddy C.A., Zippe C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 2002, 52:704-711.
10. Zelefsky M., Ben-Porat L., Scher H., Chan H., Fearn P., Fuks Z., et al. Outcome predictors for the increasing PSA state after definitive external beam radiotherapy for prostate cancer. J Clin Oncol 2005, 23:826-831.
11. D'Amico A., Moul J., Caroll P., et al. Surrogate end-point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003, 95:1376-1383.
12. Kim-Sing C., Pickles T. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database. Int J Radiat Oncol Biol Phys 2004, 60:463-469.
13. Pollack A., Zagars G., Kavadi V. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994, 74:670-678.
14. Sartor C., Strawderman M., Lin X., Kish K., Mc Laughlin P., Sandler H. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997, 38:941-947.
15. Lee A.K., Levy L.B., Cheung R., Kuban D. Prostate specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 2005, 63:456-462.
16. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:59-66.
17. Ceci F., Castellucci P., Graziani T., Schiavina R., Brunocilla E., Mazzarotto R., et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 2014, 41:878-886.
18. Giovacchini G., Picchio M., Garcia-Parra R., Briganti A., Abdollah F., Gianolli L., et al. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy. J Nucl Med 2014, 55:233-241.
19. Agarwal P.K., Sadetsky N., Konety B.R., Resnick M.I., Carroll P.R. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008, 112:307-314.
20. Shipley W., Lu J., Pilepich M., Heydon K., Roach M., Wolkov H., et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002, 54:1302-1310.
21. Taylor L.G., Canfield S.E., Du X.L. Review of major adverse effects of androgen deprivation therapy in men with prostate cancer. Cancer 2009, 115:2388-2399.
22. The Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997, 79:235-246.
23. Studer U., Hauri D., Hanselmann S., Chollet D., Leisinger H., Gasser T., et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trail SAKK 08/88. J Clin Oncol 2004, 22:4109-4118.
24. Studer U., Whelan P., Albrecht W., Casselman J., de Reijke T., Hauri D., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trail 30891. J Clin Oncol 2006, 24:1868-1876.
25. Schroder F.H., Kurth K.H., Fossa S.D., Hoekstra W., Karthaus P.P., De Prijck L., et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13years of follow-up (a randomised controlled trial). Eur Urol 2009, 55:14-22.
26. Loblaw D.A., Virgo K.S., Nam R., Somerfield M.R., Ben-Josef E., Mendelson D.S., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007, 25:1596-1605.
27. Moul J., Wu H., Sun L., Mc Leod D., Amling C., Donahue T., et al. Early versus delayed hormonal treatment therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141-1147.
28. Lu-Yao G.L., Albertsen P.C., Moore D.F., Shih W., Lin Y., Di Paola R.S., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008, 300:173-181.
29. Faria S.L., Mahmud S., Souhami L., David M., Duclos M., Shenouda G., et al. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology 2006, 67:142-146.
30. Souhami L., Bae K., Pilepich M., Sandler H. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol Biol Phys 2010, 78:1301-1306.
31. Mydin A.R., Dunne M.T., Finn M.A., Armstrong J.G. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy - a secondary analysis of Irish clinical oncology research group 97-01. Int J Radiat Oncol Biol Phys 2013, 85:101-108.
32. Pinover W., Horwitz E., Hanlon A., Uzzo R.G., Hanks G.E. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003, 97:1127-1133.
33. Tenenholz T.C., Shields C., Ramesh V.R., Tercilla O., Hagan M.P. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urol Oncol 2007, 25:101-109.
34. Stewart A., Scher H., Chen M., Mc Leod D., Caroll P., Moul J., et al. Prostate specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate specific antigen failure. J Clin Oncol 2006, 23:6556-6560.
35. Nguyen P.L., Chen M.H., Beard C.J., Suh W.W., Choueiri T.K., Efstathiou J.A., et al. Comorbidity, body mass index, and age and the risk of nonprostate cancer-specific mortality after a postradiation prostate specific antigen recurrence. Cancer 2010, 116:610-615.
36. Lofters A., Juffs H., Pond G., Tannock I.F. PSA-itis: knowledge of serum prostate specific antigen and other causes of anxiety in man with metastatic prostate cancer. J Urol 2002, 168:2516-2520.
37. Dale W., Hemmerich J., Bylow K., Mohile S., Mullaney M., Stadler W.M. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol 2009, 27:1557-1563.
38. Mottet N. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?. Eur Urol 2013, 63:121-122. [discussion 123-4].
39. Crook J.M., O'Callaghan C.J., Duncan G., Dearnaley D.P., Higano C.S., Horwitz E.M., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012, 367:895-903.
40. Calais da Silva F.E., Bono A.V., Whelan P., Brausi M., Marques Queimadelos A., Martin J.A., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009, 55:1269-1277.
41. Yu E.Y., Gulati R., Telesca D., Jiang P., Tam S., Russell K.J., et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010, 28:2668-2673.
42. Schroder F., Bangma C., Angulo J.C., Alcaraz A., Colombel M., McNicholas T., et al. Dutasteride treatment over 2years delays prostate specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol 2012, 63:779-787.
43. Monk J.P., Halabi S., Picus J., Hussain A., Philips G., Kaplan E., et al. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer 2011, 118:4139-4147.
44. Smith M.R., Manola J., Kaufman D.S., Oh W.K., Bubley G.J., Kantoff P.W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006, 24:2723-2728.
45. Schroder F.H., Roobol M.J., Boeve E.R., de Mutsert R., Zuijdgeest-van Leeuwen S.D., Kersten I., et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005, 48:922-930. [discussion 930-1].
46. Paller C.J., Antonarakis E.S. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 2013, 11:14-23.
47. Taplin M.E., Xie W., Bubley G.J., Ernstoff M.S., Walsh W., Morganstern D.E., et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006, 24:5408-5413.
48. Moussaid Y., Bonardel G., Jacob J., Métivier D., Gontier E., Bauduceau O., et al. Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma. Cancer Radiother 2013, 17:259-264.
49. nomograms.mskcc.org [homepage on the Internet]. Prostate cancer nomograms: PSA doubling time 2014, Memorial Sloan Kettering Cancer Center, New York, URL: http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx.